Meta AnalysisID 4023
蛋白酶抑制剂及母亲抗逆转录病毒治疗时机对小于胎龄儿风险的影响：一项系统评价与Meta分析
CRD42020218091
What is the risk of giving birth to an SGA infant for women receiving HAART with a PI during pregnancy compared to those receiving HAART without a PI? Is there any difference in the risk of giving birth to an SGA infant
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 4023
- Evidence Id
- 12581
- Core Evidence Id
- 12581
- Source Meta Analysis Id
- 3981
- Herb2 Meta Analysis Id
- HBMA003981
- Crd Id
- CRD42020218091
- Title
- Protease inhibitors and timing of maternal antiretroviral treatment on the risk of having a small for gestational age infant: a systematic review and meta-analysis
- Review Question
- What is the risk of giving birth to an SGA infant for women receiving HAART with a PI during pregnancy compared to those receiving HAART without a PI? Is there any difference in the risk of giving birth to an SGA infant when HAART was initiated before conception compared to after conception?
- Study Type Included
- All studies will be included, except case reports and letters.
- Condition Being Studied
- HIV
- Participant
- Women on highly active antiretroviral treatment in pregnancy
- Animal
- Human Disease Modelled
- Intervention
- 1: Maternal use of HAART that include a protease inhibitor. 2: Maternal use of HAART that is initiated from before pregnancy.
- Comparator Control
- 1: HAART that does not include a protease inhibitor. 2: Maternal use of HAART initiated in pregnancy.
- Main Outcome
- Small for gestational age (defined as < 10th percentile for their gestational age) Measures of effect Relative risks, odds ratios. Pooled estimate will be adjusted odds ratio.
- Outcome Measure
- Additional Outcome
- Study Method
- Epidemiologic, Meta-analysis, Systematic review
- Keyword
- Anti-Retroviral Agents; Enzyme Therapy; Gestational Age; HIV Infections; Humans; Infant; Infant, Newborn; Infant, Small for Gestational Age; Protease Inhibitors
- Contact
- Tormod Rebnord [email protected]
- Organisational Affiliation
- University of Bergen www.uib.no
- Funding Source
- University of Bergen Grant number(s) <span style=font-size: 14px>State the funder, grant or award number and the date of award</span>
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Norway
- Review Stage
- Review Completed not published
- First Submission Date
- 2020-10-29
- Registration Date
- 2020-11-29
- Anticipated Start Date
- 2020-10-30
- Anticipated Completion Date
- 2023-04-01
- Title Cn
- 蛋白酶抑制剂及母亲抗逆转录病毒治疗时机对小于胎龄儿风险的影响：一项系统评价与Meta分析
- Title En
- Protease inhibitors and timing of maternal antiretroviral treatment on the risk of having a small for gestational age infant: a systematic review and meta-analysis
- Bilingual Status
- complete